Inspire Medical Systems (NYSE:INSP) Given New $220.00 Price Target at Morgan Stanley

Inspire Medical Systems (NYSE:INSP) had its price objective lowered by Morgan Stanley from $230.00 to $220.00 in a research note released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

INSP has been the topic of several other research reports. KeyCorp reiterated an “overweight” rating and set a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $260.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Stifel Nicolaus cut their price objective on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research report on Tuesday, January 21st. Robert W. Baird lifted their target price on Inspire Medical Systems from $240.00 to $252.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Bank of America raised Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price target for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Stock Performance

NYSE:INSP opened at $183.17 on Tuesday. The stock has a 50-day simple moving average of $189.57 and a two-hundred day simple moving average of $190.98. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40. The firm has a market capitalization of $5.49 billion, a PE ratio of 171.18 and a beta of 1.32.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. Equities analysts forecast that Inspire Medical Systems will post 1.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Several institutional investors have recently modified their holdings of the stock. First Horizon Advisors Inc. lifted its position in Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after buying an additional 124 shares during the last quarter. True Wealth Design LLC purchased a new stake in shares of Inspire Medical Systems in the third quarter valued at $30,000. Farther Finance Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after acquiring an additional 139 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Inspire Medical Systems by 559.3% in the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after acquiring an additional 151 shares during the last quarter. Finally, Harbour Investments Inc. boosted its stake in shares of Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after purchasing an additional 99 shares during the period. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.